Psoriatic Arthritis
Conference Coverage
Pandemic puts patients with psoriatic disease off seeking medical help
Both the physical and mental health of people with psoriasis and psoriatic arthritis has been affected by the ongoing COVID-19 pandemic.
From the Journals
Psoriasis registry study finds normal pregnancy outcomes
Pregnancy outcomes such as spontaneous abortion, neonatal problems, and congenital anomalies among women with moderate to severe psoriasis were...
Conference Coverage
Anybody for a nanobody? Novel psoriasis therapy impresses in phase 2b
Sonelokinab, which inhibits interleukin-17A/F, provided exceptionally rapid clinical improvement.
From the Journals
Rheumatologic disease activity an important influencer of COVID-19 death risk
COVID-19 Global Rheumatology Alliance physician registry data highlight need to maintain adequate disease control to lower risk for death from...
News from the FDA/CDC
FDA alert confirms heart and cancer risks with tofacitinib (Xeljanz)
Completed safety clinical trial shows occurrence of heart-related events and cancer in RA patients taking the Janus kinase inhibitor is higher...
From the Journals
In head-to-head trial, two biologics differ markedly for control of psoriasis
For psoriasis, a novel IL-17A/-17F inhibitor was more effective than the IL-12/-23 inhibitor ustekinumab.
Conference Coverage
Guselkumab maintains psoriasis efficacy long after discontinuation
A potential flexible dosing indication for the IL-23 inhibitor is under study.
Conference Coverage
Deucravacitinib offers biologic-like psoriasis efficacy in oral form
Novel anti-inflammatory mechanism involves selective TYK2 inhibition.
From the Journals
Osteoporosis prevalence in PsA similar to general population
In this longitudinal cohort study, none of the factors associated with a higher likelihood of having a bone mineral density (BMD) test were...
Feature
COVID-19 vaccines: Safe for immunocompromised patients?
Data are limited thus far, and the safety and efficacy of the COVID-19 vaccines in immunocompromised patients remain unknown.
From the Journals
Synovial, skin gene expression differences may explain PsA treatment responses
Different expression of genes in the synovial tissue and skin in people with psoriatic arthritis may affect their response to treatment.